Compile Data Set for Download or QSAR

Found 697 hits with Last Name = 'takekawa' and Initial = 's'   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Melanin-concentrating hormone receptor 1 (RAT)	BDBM50150715 (4''-Fluoro-biphenyl-4-carboxylic acid (6-dimethyla...) Show SMILES CN(C)CC1CCc2cc(NC(=O)c3ccc(cc3)-c3ccc(F)cc3)ccc2C1 Show InChI InChI=1S/C26H27FN2O/c1-29(2)17-18-3-4-23-16-25(14-11-22(23)15-18)28-26(30)21-7-5-19(6-8-21)20-9-12-24(27)13-10-20/h5-14,16,18H,3-4,15,17H2,1-2H3,(H,28,30)	Reactome pathway KEGG UniProtKB/SwissProt GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	Article PubMed	8.60	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Chemical Industries, Ltd. Curated by PDSP Ki Database									Eur J Pharmacol 438: 129-35 (2002) Article DOI: 10.1016/s0014-2999(02)01314-6 BindingDB Entry DOI: 10.7270/Q2GX495R
					More data for this Ligand-Target Pair
Atrial natriuretic peptide receptor 3 (Homo sapiens (Human))	BDBM50254108 (CHEMBL4062470) Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](Cc1ccccc1)NC(C)=O)[C@@H](C)CC)C(N)=O |r| Show InChI InChI=1S/C60H95N15O15/c1-7-33(3)48(50(61)81)72-52(83)39(22-15-25-64-60(62)63)68-55(86)42(30-47(79)80)70-58(89)49(34(4)8-2)73-57(88)44-23-16-26-74(44)46(78)31-65-51(82)35(5)66-53(84)41(29-38-20-13-10-14-21-38)69-56(87)45-24-17-27-75(45)59(90)43(32-76)71-54(85)40(67-36(6)77)28-37-18-11-9-12-19-37/h9,11-12,18-19,33-35,38-45,48-49,76H,7-8,10,13-17,20-32H2,1-6H3,(H2,61,81)(H,65,82)(H,66,84)(H,67,77)(H,68,86)(H,69,87)(H,70,89)(H,71,85)(H,72,83)(H,73,88)(H,79,80)(H4,62,63,64)/t33-,34-,35+,39-,40+,41-,42-,43-,44-,45+,48-,49-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.0540	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Ltd Curated by ChEMBL					Assay Description Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubat...				Bioorg Med Chem Lett 27: 3542-3545 (2017) Article DOI: 10.1016/j.bmcl.2017.05.061 BindingDB Entry DOI: 10.7270/Q2F19241
					More data for this Ligand-Target Pair
Atrial natriuretic peptide receptor 3 (Homo sapiens (Human))	BDBM50254063 (CHEMBL4102000) Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CSSC[C@H](NCC(=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO |r| Show InChI InChI=1S/C127H203N45O39S3/c1-9-64(6)99-121(209)150-53-94(182)151-65(7)100(188)154-76(34-35-91(129)179)108(196)166-85(56-174)103(191)149-54-96(184)153-78(43-62(2)3)115(203)171-97(185)51-146-89(119(207)163-82(48-92(130)180)113(201)168-86(57-175)116(204)162-81(46-67-23-14-11-15-24-67)112(200)157-73(27-18-39-143-125(135)136)106(194)165-84(122(210)211)47-68-30-32-69(178)33-31-68)60-213-214-61-90(170-118(206)88(59-177)169-117(205)87(58-176)167-107(195)74(28-19-40-144-126(137)138)155-105(193)72(26-17-38-142-124(133)134)156-111(199)79(44-63(4)5)160-101(189)70(128)55-173)120(208)161-80(45-66-21-12-10-13-22-66)102(190)148-50-93(181)147-52-95(183)152-71(25-16-37-141-123(131)132)104(192)159-77(36-42-212-8)109(197)164-83(49-98(186)187)114(202)158-75(110(198)172-99)29-20-41-145-127(139)140/h10-15,21-24,30-33,62-65,70-90,99,146,173-178H,9,16-20,25-29,34-61,128H2,1-8H3,(H2,129,179)(H2,130,180)(H,147,181)(H,148,190)(H,149,191)(H,150,209)(H,151,182)(H,152,183)(H,153,184)(H,154,188)(H,155,193)(H,156,199)(H,157,200)(H,158,202)(H,159,192)(H,160,189)(H,161,208)(H,162,204)(H,163,207)(H,164,197)(H,165,194)(H,166,196)(H,167,195)(H,168,201)(H,169,205)(H,170,206)(H,172,198)(H,186,187)(H,210,211)(H4,131,132,141)(H4,133,134,142)(H4,135,136,143)(H4,137,138,144)(H4,139,140,145)(H,171,185,203)/t64-,65-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,99-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.0580	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Ltd Curated by ChEMBL					Assay Description Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubat...				Bioorg Med Chem Lett 27: 3542-3545 (2017) Article DOI: 10.1016/j.bmcl.2017.05.061 BindingDB Entry DOI: 10.7270/Q2F19241
					More data for this Ligand-Target Pair
Atrial natriuretic peptide receptor 3 (Homo sapiens (Human))	BDBM50254062 (CHEMBL4060314) Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)NC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)CNC(=O)[C@@H](CO)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H](CO)NC(=O)[C@@H](Cc1ccccc1)NC(=O)CO)[C@@H](C)CC)C(=O)NC |r| Show InChI InChI=1S/C62H99N15O19/c1-7-33(3)50(59(94)64-5)74-53(88)39(20-15-21-66-62(63)65-6)69-56(91)42(26-49(85)86)71-60(95)51(34(4)8-2)75-58(93)45-24-37(81)28-76(45)48(84)27-67-52(87)43(30-78)72-55(90)41(23-36-18-13-10-14-19-36)70-57(92)46-25-38(82)29-77(46)61(96)44(31-79)73-54(89)40(68-47(83)32-80)22-35-16-11-9-12-17-35/h9,11-12,16-17,33-34,36-46,50-51,78-82H,7-8,10,13-15,18-32H2,1-6H3,(H,64,94)(H,67,87)(H,68,83)(H,69,91)(H,70,92)(H,71,95)(H,72,90)(H,73,89)(H,74,88)(H,75,93)(H,85,86)(H3,63,65,66)/t33-,34-,37+,38-,39-,40+,41-,42-,43+,44-,45-,46+,50-,51-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.0790	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Ltd Curated by ChEMBL					Assay Description Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubat...				Bioorg Med Chem Lett 27: 3542-3545 (2017) Article DOI: 10.1016/j.bmcl.2017.05.061 BindingDB Entry DOI: 10.7270/Q2F19241
					More data for this Ligand-Target Pair
Atrial natriuretic peptide receptor 3 (Homo sapiens (Human))	BDBM50254060 (CHEMBL4061379) Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](Cc1ccccc1)NC(C)=O)[C@@H](C)CC)C(=O)NC |r| Show InChI InChI=1S/C61H97N15O15/c1-8-34(3)49(58(89)64-7)73-52(83)40(23-16-26-65-61(62)63)69-55(86)43(31-48(80)81)71-59(90)50(35(4)9-2)74-57(88)45-24-17-27-75(45)47(79)32-66-51(82)36(5)67-53(84)42(30-39-21-14-11-15-22-39)70-56(87)46-25-18-28-76(46)60(91)44(33-77)72-54(85)41(68-37(6)78)29-38-19-12-10-13-20-38/h10,12-13,19-20,34-36,39-46,49-50,77H,8-9,11,14-18,21-33H2,1-7H3,(H,64,89)(H,66,82)(H,67,84)(H,68,78)(H,69,86)(H,70,87)(H,71,90)(H,72,85)(H,73,83)(H,74,88)(H,80,81)(H4,62,63,65)/t34-,35-,36+,40-,41+,42-,43-,44-,45-,46+,49-,50-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Patents Similars	Article PubMed	n/a	n/a	0.0870	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Ltd Curated by ChEMBL					Assay Description Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubat...				Bioorg Med Chem Lett 27: 3542-3545 (2017) Article DOI: 10.1016/j.bmcl.2017.05.061 BindingDB Entry DOI: 10.7270/Q2F19241
					More data for this Ligand-Target Pair
Atrial natriuretic peptide receptor 1 (Homo sapiens (Human))	BDBM50254063 (CHEMBL4102000) Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CSSC[C@H](NCC(=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO |r| Show InChI InChI=1S/C127H203N45O39S3/c1-9-64(6)99-121(209)150-53-94(182)151-65(7)100(188)154-76(34-35-91(129)179)108(196)166-85(56-174)103(191)149-54-96(184)153-78(43-62(2)3)115(203)171-97(185)51-146-89(119(207)163-82(48-92(130)180)113(201)168-86(57-175)116(204)162-81(46-67-23-14-11-15-24-67)112(200)157-73(27-18-39-143-125(135)136)106(194)165-84(122(210)211)47-68-30-32-69(178)33-31-68)60-213-214-61-90(170-118(206)88(59-177)169-117(205)87(58-176)167-107(195)74(28-19-40-144-126(137)138)155-105(193)72(26-17-38-142-124(133)134)156-111(199)79(44-63(4)5)160-101(189)70(128)55-173)120(208)161-80(45-66-21-12-10-13-22-66)102(190)148-50-93(181)147-52-95(183)152-71(25-16-37-141-123(131)132)104(192)159-77(36-42-212-8)109(197)164-83(49-98(186)187)114(202)158-75(110(198)172-99)29-20-41-145-127(139)140/h10-15,21-24,30-33,62-65,70-90,99,146,173-178H,9,16-20,25-29,34-61,128H2,1-8H3,(H2,129,179)(H2,130,180)(H,147,181)(H,148,190)(H,149,191)(H,150,209)(H,151,182)(H,152,183)(H,153,184)(H,154,188)(H,155,193)(H,156,199)(H,157,200)(H,158,202)(H,159,192)(H,160,189)(H,161,208)(H,162,204)(H,163,207)(H,164,197)(H,165,194)(H,166,196)(H,167,195)(H,168,201)(H,169,205)(H,170,206)(H,172,198)(H,186,187)(H,210,211)(H4,131,132,141)(H4,133,134,142)(H4,135,136,143)(H4,137,138,144)(H4,139,140,145)(H,171,185,203)/t64-,65-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,99-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.0940	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Ltd Curated by ChEMBL					Assay Description Displacement of [125I]-human ANP from human NPR-1 incubated for 2 hrs by top count method				Bioorg Med Chem Lett 27: 3542-3545 (2017) Article DOI: 10.1016/j.bmcl.2017.05.061 BindingDB Entry DOI: 10.7270/Q2F19241
					More data for this Ligand-Target Pair
Atrial natriuretic peptide receptor 3 (Homo sapiens (Human))	BDBM50254096 (CHEMBL4099663) Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)NC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H](CO)NC(=O)[C@@H](Cc1ccccc1)NC(C)=O)[C@@H](C)CC)C(=O)NC |r| Show InChI InChI=1S/C62H99N15O17/c1-9-33(3)50(59(92)64-7)74-53(86)41(22-17-23-66-62(63)65-8)70-56(89)44(28-49(83)84)72-60(93)51(34(4)10-2)75-58(91)46-26-39(80)30-76(46)48(82)29-67-52(85)35(5)68-54(87)43(25-38-20-15-12-16-21-38)71-57(90)47-27-40(81)31-77(47)61(94)45(32-78)73-55(88)42(69-36(6)79)24-37-18-13-11-14-19-37/h11,13-14,18-19,33-35,38-47,50-51,78,80-81H,9-10,12,15-17,20-32H2,1-8H3,(H,64,92)(H,67,85)(H,68,87)(H,69,79)(H,70,89)(H,71,90)(H,72,93)(H,73,88)(H,74,86)(H,75,91)(H,83,84)(H3,63,65,66)/t33-,34-,35+,39+,40-,41-,42+,43-,44-,45-,46-,47+,50-,51-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.0990	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Ltd Curated by ChEMBL					Assay Description Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubat...				Bioorg Med Chem Lett 27: 3542-3545 (2017) Article DOI: 10.1016/j.bmcl.2017.05.061 BindingDB Entry DOI: 10.7270/Q2F19241
					More data for this Ligand-Target Pair
Atrial natriuretic peptide receptor 3 (Homo sapiens (Human))	BDBM50254091 (CHEMBL4061318) Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)NCC(N)=O |r| Show InChI InChI=1S/C57H95N19O15/c1-5-31(3)46(54(90)67-26-41(59)78)75-52(88)37(20-14-22-65-57(62)63)72-53(89)39(25-45(82)83)73-55(91)47(32(4)6-2)76-51(87)36(19-13-21-64-56(60)61)70-43(80)28-66-42(79)27-68-49(85)38(24-34-17-11-8-12-18-34)71-44(81)29-69-50(86)40(30-77)74-48(84)35(58)23-33-15-9-7-10-16-33/h7,9-10,15-16,31-32,34-40,46-47,77H,5-6,8,11-14,17-30,58H2,1-4H3,(H2,59,78)(H,66,79)(H,67,90)(H,68,85)(H,69,86)(H,70,80)(H,71,81)(H,72,89)(H,73,91)(H,74,84)(H,75,88)(H,76,87)(H,82,83)(H4,60,61,64)(H4,62,63,65)/t31-,32-,35+,36-,37-,38-,39-,40-,46-,47-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Patents Similars	Article PubMed	n/a	n/a	0.120	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Ltd Curated by ChEMBL					Assay Description Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubat...				Bioorg Med Chem Lett 27: 3542-3545 (2017) Article DOI: 10.1016/j.bmcl.2017.05.061 BindingDB Entry DOI: 10.7270/Q2F19241
					More data for this Ligand-Target Pair
Atrial natriuretic peptide receptor 3 (Homo sapiens (Human))	BDBM50254094 (CHEMBL4076904) Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)NCC(N)=O |r| Show InChI InChI=1S/C56H90N16O15/c1-5-31(3)46(54(86)63-26-41(58)74)70-51(83)36(19-13-21-61-56(59)60)67-52(84)38(25-45(78)79)68-55(87)47(32(4)6-2)71-53(85)40-20-14-22-72(40)44(77)29-62-42(75)27-64-49(81)37(24-34-17-11-8-12-18-34)66-43(76)28-65-50(82)39(30-73)69-48(80)35(57)23-33-15-9-7-10-16-33/h7,9-10,15-16,31-32,34-40,46-47,73H,5-6,8,11-14,17-30,57H2,1-4H3,(H2,58,74)(H,62,75)(H,63,86)(H,64,81)(H,65,82)(H,66,76)(H,67,84)(H,68,87)(H,69,80)(H,70,83)(H,71,85)(H,78,79)(H4,59,60,61)/t31-,32-,35+,36-,37-,38-,39-,40-,46-,47-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.120	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Ltd Curated by ChEMBL					Assay Description Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubat...				Bioorg Med Chem Lett 27: 3542-3545 (2017) Article DOI: 10.1016/j.bmcl.2017.05.061 BindingDB Entry DOI: 10.7270/Q2F19241
					More data for this Ligand-Target Pair
Atrial natriuretic peptide receptor 3 (Homo sapiens (Human))	BDBM50254106 (CHEMBL4084160) Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)NCC(N)=O |r| Show InChI InChI=1S/C60H99N19O15/c1-5-33(3)48(56(92)70-29-44(62)81)77-53(89)39(21-14-24-68-60(65)66)73-54(90)41(28-47(84)85)75-57(93)49(34(4)6-2)78-52(88)38(20-13-23-67-59(63)64)72-46(83)31-69-45(82)30-71-51(87)40(27-36-18-11-8-12-19-36)74-55(91)43-22-15-25-79(43)58(94)42(32-80)76-50(86)37(61)26-35-16-9-7-10-17-35/h7,9-10,16-17,33-34,36-43,48-49,80H,5-6,8,11-15,18-32,61H2,1-4H3,(H2,62,81)(H,69,82)(H,70,92)(H,71,87)(H,72,83)(H,73,90)(H,74,91)(H,75,93)(H,76,86)(H,77,89)(H,78,88)(H,84,85)(H4,63,64,67)(H4,65,66,68)/t33-,34-,37+,38-,39-,40-,41-,42-,43+,48-,49-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.130	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Ltd Curated by ChEMBL					Assay Description Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubat...				Bioorg Med Chem Lett 27: 3542-3545 (2017) Article DOI: 10.1016/j.bmcl.2017.05.061 BindingDB Entry DOI: 10.7270/Q2F19241
					More data for this Ligand-Target Pair
Atrial natriuretic peptide receptor 3 (Homo sapiens (Human))	BDBM50254061 (CHEMBL4089530) Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)NC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](Cc1ccccc1)NC(C)=O)[C@@H](C)CC)C(=O)NC |r| Show InChI InChI=1S/C62H99N15O15/c1-9-35(3)50(59(90)64-7)74-53(84)41(24-17-27-66-62(63)65-8)70-56(87)44(32-49(81)82)72-60(91)51(36(4)10-2)75-58(89)46-25-18-28-76(46)48(80)33-67-52(83)37(5)68-54(85)43(31-40-22-15-12-16-23-40)71-57(88)47-26-19-29-77(47)61(92)45(34-78)73-55(86)42(69-38(6)79)30-39-20-13-11-14-21-39/h11,13-14,20-21,35-37,40-47,50-51,78H,9-10,12,15-19,22-34H2,1-8H3,(H,64,90)(H,67,83)(H,68,85)(H,69,79)(H,70,87)(H,71,88)(H,72,91)(H,73,86)(H,74,84)(H,75,89)(H,81,82)(H3,63,65,66)/t35-,36-,37+,41-,42+,43-,44-,45-,46-,47+,50-,51-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem Patents Similars	Article PubMed	n/a	n/a	0.140	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Ltd Curated by ChEMBL					Assay Description Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubat...				Bioorg Med Chem Lett 27: 3542-3545 (2017) Article DOI: 10.1016/j.bmcl.2017.05.061 BindingDB Entry DOI: 10.7270/Q2F19241
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50451011 (CHEMBL4216889) Show SMILES CC[C@](C)(NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1ccncc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C82H140N28O19/c1-7-82(6,109-72(124)57(41-48-22-12-9-13-23-48)105-69(121)56(42-49-31-37-93-38-32-49)104-67(119)51(26-17-35-95-79(89)90)101-73(125)60-28-19-39-110(60)75(127)59(44-111)97-46(3)113)77(129)106-58(43-62(85)115)70(122)99-53(24-14-15-33-83)71(123)108-81(4,5)76(128)107-63(45(2)112)74(126)102-52(27-18-36-96-80(91)92)65(117)100-54(29-30-61(84)114)68(120)98-50(25-16-34-94-78(87)88)66(118)103-55(64(86)116)40-47-20-10-8-11-21-47/h31-32,37-38,45,47-48,50-60,63,111-112H,7-30,33-36,39-44,83H2,1-6H3,(H2,84,114)(H2,85,115)(H2,86,116)(H,97,113)(H,98,120)(H,99,122)(H,100,117)(H,101,125)(H,102,126)(H,103,118)(H,104,119)(H,105,121)(H,106,129)(H,107,128)(H,108,123)(H,109,124)(H4,87,88,94)(H4,89,90,95)(H4,91,92,96)/t45-,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60-,63+,82+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.160	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair
Atrial natriuretic peptide receptor 3 (Homo sapiens (Human))	BDBM50254095 (CHEMBL4084171) Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](Cc1ccccc1)NC(C)=O)[C@@H](C)CC)C(=O)NCC(N)=O |r| Show InChI InChI=1S/C62H98N16O16/c1-7-34(3)50(59(92)67-31-47(63)81)75-53(86)40(22-15-25-66-62(64)65)71-56(89)43(30-49(83)84)73-60(93)51(35(4)8-2)76-58(91)45-23-16-26-77(45)48(82)32-68-52(85)36(5)69-54(87)42(29-39-20-13-10-14-21-39)72-57(90)46-24-17-27-78(46)61(94)44(33-79)74-55(88)41(70-37(6)80)28-38-18-11-9-12-19-38/h9,11-12,18-19,34-36,39-46,50-51,79H,7-8,10,13-17,20-33H2,1-6H3,(H2,63,81)(H,67,92)(H,68,85)(H,69,87)(H,70,80)(H,71,89)(H,72,90)(H,73,93)(H,74,88)(H,75,86)(H,76,91)(H,83,84)(H4,64,65,66)/t34-,35-,36+,40-,41+,42-,43-,44-,45-,46+,50-,51-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.190	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Ltd Curated by ChEMBL					Assay Description Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubat...				Bioorg Med Chem Lett 27: 3542-3545 (2017) Article DOI: 10.1016/j.bmcl.2017.05.061 BindingDB Entry DOI: 10.7270/Q2F19241
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50460003 (CHEMBL4224835) Show SMILES CCCCCCCCCCCCCCCC(=O)NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](CCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CO)C(=O)N1C[C@@H](O)C[C@@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccncc1)C(=O)N[C@@H](CC1CCCCC1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCNC(=O)C1CCNCC1)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O)C(O)=O |r,wU:117.121,147.152,167.172,56.57,63.64,92.95,19.18,28.29,70.72,wD:109.113,140.148,141.147,158.163,178.183,66.68,81.83,22.25,(51.58,-3.44,;50.25,-4.23,;48.91,-3.49,;47.58,-4.29,;46.24,-3.55,;44.92,-4.35,;43.56,-3.61,;42.23,-4.41,;40.89,-3.67,;39.55,-4.46,;38.21,-3.73,;36.88,-4.51,;35.54,-3.78,;34.23,-4.58,;32.88,-3.84,;31.53,-4.63,;31.58,-6.19,;30.19,-3.89,;28.87,-4.69,;27.51,-3.94,;26.21,-4.75,;24.85,-3.99,;24.82,-2.44,;26.15,-1.65,;27.49,-2.4,;23.47,-1.69,;23.45,-.14,;22.14,-2.48,;20.79,-1.73,;19.46,-2.52,;18.1,-1.77,;16.78,-2.57,;16.8,-4.11,;15.43,-1.81,;14.1,-2.61,;12.75,-1.85,;11.42,-2.65,;10.08,-1.89,;8.75,-2.69,;7.4,-1.94,;6.08,-2.73,;6.1,-4.27,;7.46,-5.01,;7.49,-6.57,;8.85,-7.31,;8.88,-8.86,;10.25,-9.6,;10.28,-11.15,;11.64,-11.9,;12.96,-11.09,;11.66,-13.44,;13.02,-14.18,;13.05,-15.73,;14.41,-16.48,;15.74,-15.68,;14.45,-18.01,;15.99,-18.14,;16.88,-16.89,;18.41,-17.04,;16.63,-19.54,;15.75,-20.8,;18.16,-19.69,;19.17,-18.53,;20.58,-19.14,;21.92,-18.36,;20.44,-20.67,;18.94,-21.01,;18.33,-22.42,;16.8,-22.6,;19.25,-23.65,;20.78,-23.47,;21.39,-22.06,;22.92,-21.88,;23.53,-20.47,;25.06,-20.29,;25.67,-18.88,;27.2,-18.7,;24.75,-17.64,;21.7,-24.72,;21.08,-26.13,;23.23,-24.55,;24.14,-25.78,;23.53,-27.19,;24.44,-28.44,;23.82,-29.84,;24.73,-31.08,;26.27,-30.91,;26.88,-29.49,;25.97,-28.25,;25.67,-25.61,;26.28,-24.2,;26.59,-26.85,;28.12,-26.67,;28.73,-25.26,;30.26,-25.09,;31.17,-26.33,;32.71,-26.16,;33.32,-24.75,;32.4,-23.51,;30.87,-23.67,;29.03,-27.91,;28.42,-29.33,;30.56,-27.73,;31.47,-28.97,;32.8,-28.19,;32.81,-29.73,;30.85,-30.39,;29.33,-30.56,;31.77,-31.63,;31.15,-33.04,;29.62,-33.21,;29,-34.62,;27.47,-34.79,;29.92,-35.86,;32.06,-34.28,;31.44,-35.69,;33.59,-34.11,;34.51,-35.35,;36.03,-35.18,;36.65,-33.77,;38.18,-33.6,;38.8,-32.19,;40.33,-32.02,;40.95,-30.61,;40.03,-29.37,;42.48,-30.44,;43.38,-31.68,;44.9,-31.51,;45.53,-30.11,;44.62,-28.86,;43.08,-29.03,;33.89,-36.76,;32.36,-36.93,;34.8,-38,;34.18,-39.41,;32.96,-40.34,;32.76,-38.81,;35.09,-40.65,;34.48,-42.06,;36.63,-40.49,;37.54,-41.72,;36.92,-43.14,;35.38,-43.3,;37.83,-44.38,;39.07,-41.56,;39.68,-40.14,;39.97,-42.8,;41.5,-42.63,;42.13,-41.23,;43.66,-41.06,;44.28,-39.65,;45.81,-39.49,;46.43,-38.08,;47.97,-37.91,;45.53,-36.84,;42.41,-43.88,;41.79,-45.29,;43.94,-43.71,;44.85,-44.96,;44.23,-46.36,;42.7,-46.53,;42.08,-47.94,;40.55,-48.1,;42.98,-49.18,;46.38,-44.79,;47.01,-43.38,;47.29,-46.03,;48.82,-45.87,;49.45,-44.46,;50.98,-44.3,;51.6,-42.89,;53.13,-42.72,;53.75,-41.31,;55.28,-41.15,;52.84,-40.07,;49.73,-47.11,;49.11,-48.52,;51.26,-46.95,;52.17,-48.19,;51.55,-49.6,;52.46,-50.84,;51.83,-52.24,;52.73,-53.48,;54.26,-53.32,;54.89,-51.92,;53.98,-50.66,;53.7,-48.03,;54.61,-49.27,;54.32,-46.62,;20.76,-.18,;22.1,.63,;19.41,.58,)| Show InChI InChI=1S/C128H221N33O31/c1-7-8-9-10-11-12-13-14-15-16-17-18-25-41-102(167)146-75-84-42-44-85(45-43-84)109(173)153-93(121(185)186)47-49-103(168)140-58-31-64-189-66-68-191-69-67-190-65-32-59-141-104(169)78-192-79-105(170)147-98(77-162)120(184)161-76-87(164)73-99(161)118(182)151-89(39-29-56-144-125(134)135)112(176)155-95(72-83-50-60-138-61-51-83)114(178)156-96(71-82-35-23-20-24-36-82)117(181)160-127(3,4)122(187)157-97(74-101(130)166)115(179)149-91(37-26-27-54-142-108(172)86-52-62-139-63-53-86)116(180)159-128(5,6)123(188)158-106(80(2)163)119(183)152-90(40-30-57-145-126(136)137)110(174)150-92(46-48-100(129)165)113(177)148-88(38-28-55-143-124(132)133)111(175)154-94(107(131)171)70-81-33-21-19-22-34-81/h50-51,60-61,80-82,84-99,106,139,162-164H,7-49,52-59,62-79H2,1-6H3,(H2,129,165)(H2,130,166)(H2,131,171)(H,140,168)(H,141,169)(H,142,172)(H,146,167)(H,147,170)(H,148,177)(H,149,179)(H,150,174)(H,151,182)(H,152,183)(H,153,173)(H,154,175)(H,155,176)(H,156,178)(H,157,187)(H,158,188)(H,159,180)(H,160,181)(H,185,186)(H4,132,133,143)(H4,134,135,144)(H4,136,137,145)/t80-,84-,85-,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99-,106+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.190	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount micro scintillation ...				Bioorg Med Chem 26: 566-572 (2018) Article DOI: 10.1016/j.bmc.2017.12.014 BindingDB Entry DOI: 10.7270/Q22B91N1
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50460001 (CHEMBL4226347) Show SMILES CCCCCCCCCCCCCCCC(=O)NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](CCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)NCCCC[C@H](N)C(=O)NCCCC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(C)(C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1ccncc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H](CO)NC(=O)c1c[nH]cn1)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O)C(O)=O |r,wU:19.18,28.29,60.61,69.69,155.160,175.180,128.132,122.125,87.88,109.112,wD:22.25,73.74,148.156,149.155,166.171,186.191,120.122,98.100,(57.36,-43.73,;56.04,-42.9,;56.1,-41.37,;54.78,-40.54,;54.84,-39.01,;53.54,-38.19,;53.58,-36.65,;52.27,-35.83,;52.32,-34.29,;51.02,-33.46,;51.06,-31.93,;49.76,-31.1,;49.81,-29.57,;48.5,-28.76,;48.55,-27.22,;47.24,-26.37,;45.87,-27.13,;47.3,-24.84,;45.99,-24.02,;46.04,-22.48,;44.73,-21.68,;44.79,-20.13,;46.16,-19.4,;47.47,-20.23,;47.41,-21.77,;46.23,-17.85,;47.6,-17.13,;44.92,-17.03,;44.98,-15.48,;43.67,-14.65,;43.73,-13.11,;42.42,-12.28,;41.05,-13,;42.49,-10.75,;41.18,-9.91,;41.24,-8.36,;39.93,-7.54,;40,-6,;38.69,-5.18,;38.75,-3.63,;37.45,-2.81,;36.08,-3.52,;36.03,-5.08,;34.66,-5.8,;34.61,-7.35,;33.24,-8.08,;33.19,-9.63,;31.82,-10.37,;31.77,-11.91,;33.09,-12.73,;30.41,-12.64,;30.36,-14.18,;28.99,-14.9,;28.94,-16.45,;30.25,-17.27,;27.58,-17.18,;27.53,-18.71,;26.17,-19.44,;26.12,-20.98,;24.77,-21.71,;23.46,-20.89,;23.51,-19.35,;22.1,-21.62,;20.79,-20.8,;22.05,-23.16,;23.35,-23.98,;23.29,-25.52,;21.93,-26.23,;21.86,-27.77,;20.5,-28.48,;19.2,-27.67,;17.84,-28.38,;17.77,-29.92,;16.54,-27.55,;15.17,-28.27,;15.11,-29.81,;13.75,-30.52,;16.41,-30.63,;16.6,-26.01,;15.3,-25.19,;13.94,-25.91,;15.36,-23.65,;15.94,-22.22,;16.88,-23.44,;14.06,-22.83,;12.7,-23.55,;12.65,-25.09,;11.4,-22.73,;11.46,-21.19,;12.82,-20.47,;14.12,-21.3,;15.49,-20.58,;15.54,-19.04,;14.24,-18.22,;12.87,-18.93,;10.04,-23.44,;8.73,-22.62,;8.79,-21.09,;7.37,-23.34,;7.31,-24.88,;8.62,-25.7,;8.55,-27.24,;9.85,-28.06,;11.22,-27.34,;11.27,-25.8,;9.97,-24.98,;6.07,-22.52,;4.71,-23.24,;4.65,-24.78,;3.4,-22.41,;3.45,-20.87,;4.81,-20.15,;4.87,-18.61,;6.23,-17.89,;7.53,-18.71,;8.9,-17.99,;7.48,-20.25,;2.04,-23.14,;.73,-22.32,;-.63,-23.05,;.79,-20.78,;2.07,-19.92,;1.64,-18.45,;2.6,-17.23,;.1,-18.39,;-.42,-19.84,;-1.9,-20.26,;-2.27,-21.75,;-3.02,-19.19,;-2.64,-17.7,;-1.16,-17.28,;-4.49,-19.62,;-5.6,-18.55,;-5.23,-17.06,;-7.08,-18.97,;-7.6,-20.42,;-9.14,-20.37,;-9.57,-18.88,;-8.29,-18.03,;20.44,-30.02,;19.08,-30.73,;21.74,-30.85,;21.68,-32.38,;20.88,-33.7,;20.13,-32.34,;22.98,-33.21,;22.92,-34.75,;24.35,-32.5,;25.65,-33.32,;25.59,-34.86,;24.21,-35.58,;26.88,-35.69,;27.01,-32.61,;27.07,-31.07,;28.31,-33.44,;29.67,-32.73,;29.74,-31.19,;31.11,-30.48,;31.18,-28.94,;32.54,-28.23,;32.61,-26.69,;33.98,-25.98,;31.31,-25.86,;30.97,-33.55,;30.9,-35.09,;32.34,-32.84,;33.64,-33.67,;33.57,-35.21,;32.2,-35.92,;32.13,-37.46,;30.77,-38.17,;33.43,-38.29,;35,-32.96,;35.07,-31.42,;36.3,-33.79,;37.67,-33.08,;37.74,-31.54,;39.1,-30.83,;39.17,-29.29,;40.54,-28.58,;40.6,-27.04,;41.97,-26.33,;39.3,-26.21,;38.97,-33.91,;38.9,-35.44,;40.33,-33.2,;41.63,-34.02,;41.56,-35.56,;42.86,-36.39,;42.78,-37.92,;44.07,-38.75,;45.44,-38.05,;45.52,-36.51,;44.22,-35.67,;43,-33.31,;44.29,-34.14,;43.06,-31.77,;46.35,-14.76,;47.67,-15.58,;46.41,-13.21,)| Show InChI InChI=1S/C132H226N36O32/c1-7-8-9-10-11-12-13-14-15-16-17-18-25-44-105(174)152-75-86-45-47-87(48-46-86)111(179)159-95(125(193)194)50-52-106(175)145-60-33-64-197-66-68-199-69-67-198-65-34-61-147-108(177)80-200-79-107(176)146-55-28-26-39-89(133)112(180)148-56-29-27-40-93(120(188)166-132(5,6)127(196)165-109(82(2)170)123(191)158-92(43-32-59-151-130(141)142)113(181)156-94(49-51-103(134)172)116(184)154-90(41-30-57-149-128(137)138)114(182)160-96(110(136)178)70-83-35-21-19-22-36-83)155-118(186)99(74-104(135)173)164-126(195)131(3,4)167-121(189)98(71-84-37-23-20-24-38-84)162-117(185)97(72-85-53-62-143-63-54-85)161-115(183)91(42-31-58-150-129(139)140)157-122(190)102-73-88(171)77-168(102)124(192)101(78-169)163-119(187)100-76-144-81-153-100/h53-54,62-63,76,81-84,86-99,101-102,109,169-171H,7-52,55-61,64-75,77-80,133H2,1-6H3,(H2,134,172)(H2,135,173)(H2,136,178)(H,144,153)(H,145,175)(H,146,176)(H,147,177)(H,148,180)(H,152,174)(H,154,184)(H,155,186)(H,156,181)(H,157,190)(H,158,191)(H,159,179)(H,160,182)(H,161,183)(H,162,185)(H,163,187)(H,164,195)(H,165,196)(H,166,188)(H,167,189)(H,193,194)(H4,137,138,149)(H4,139,140,150)(H4,141,142,151)/t82-,86-,87-,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,101+,102-,109+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.190	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount micro scintillation ...				Bioorg Med Chem 26: 566-572 (2018) Article DOI: 10.1016/j.bmc.2017.12.014 BindingDB Entry DOI: 10.7270/Q22B91N1
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50451012 (CHEMBL4208191) Show SMILES CC[C@@](C)(NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)C(C)(C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1ccncc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C82H140N28O19/c1-7-82(6,77(129)107-63(45(2)112)74(126)102-52(27-18-36-96-80(91)92)65(117)100-54(29-30-61(84)114)68(120)98-50(25-16-34-94-78(87)88)66(118)103-55(64(86)116)40-47-20-10-8-11-21-47)109-71(123)53(24-14-15-33-83)99-70(122)58(43-62(85)115)106-76(128)81(4,5)108-72(124)57(41-48-22-12-9-13-23-48)105-69(121)56(42-49-31-37-93-38-32-49)104-67(119)51(26-17-35-95-79(89)90)101-73(125)60-28-19-39-110(60)75(127)59(44-111)97-46(3)113/h31-32,37-38,45,47-48,50-60,63,111-112H,7-30,33-36,39-44,83H2,1-6H3,(H2,84,114)(H2,85,115)(H2,86,116)(H,97,113)(H,98,120)(H,99,122)(H,100,117)(H,101,125)(H,102,126)(H,103,118)(H,104,119)(H,105,121)(H,106,128)(H,107,129)(H,108,124)(H,109,123)(H4,87,88,94)(H4,89,90,95)(H4,91,92,96)/t45-,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60-,63+,82-/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.270	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50451003 (CHEMBL4207076) Show SMILES CC[C@@](C)(NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccncc1)C(=O)N[C@@H](CC1CCCCC1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C81H140N28O19/c1-9-81(8,109-71(124)58(43-110)96-45(3)112)75(128)104-51(28-20-36-95-78(90)91)65(118)102-55(41-48-31-37-92-38-32-48)67(120)103-56(40-47-23-14-11-15-24-47)70(123)108-79(4,5)73(126)105-57(42-60(84)114)68(121)98-52(25-16-17-33-82)69(122)107-80(6,7)74(127)106-61(44(2)111)72(125)100-50(27-19-35-94-77(88)89)63(116)99-53(29-30-59(83)113)66(119)97-49(26-18-34-93-76(86)87)64(117)101-54(62(85)115)39-46-21-12-10-13-22-46/h31-32,37-38,44,46-47,49-58,61,110-111H,9-30,33-36,39-43,82H2,1-8H3,(H2,83,113)(H2,84,114)(H2,85,115)(H,96,112)(H,97,119)(H,98,121)(H,99,116)(H,100,125)(H,101,117)(H,102,118)(H,103,120)(H,104,128)(H,105,126)(H,106,127)(H,107,122)(H,108,123)(H,109,124)(H4,86,87,93)(H4,88,89,94)(H4,90,91,95)/t44-,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,61+,81-/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair
Atrial natriuretic peptide receptor 3 (Homo sapiens (Human))	BDBM50254089 (CHEMBL4081715) Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)NCC(N)=O |r| Show InChI InChI=1S/C66H112N24O18/c1-5-35(3)52(62(107)79-29-47(68)93)89-58(103)41(22-15-25-77-66(73)74)84-60(105)44(28-51(97)98)86-63(108)53(36(4)6-2)90-57(102)40(21-14-24-76-65(71)72)82-49(95)31-78-48(94)30-80-55(100)42(26-37-16-9-7-10-17-37)83-50(96)32-81-56(101)45(33-91)88-59(104)43(27-38-18-11-8-12-19-38)85-61(106)46(34-92)87-54(99)39(67)20-13-23-75-64(69)70/h8,11-12,18-19,35-37,39-46,52-53,91-92H,5-7,9-10,13-17,20-34,67H2,1-4H3,(H2,68,93)(H,78,94)(H,79,107)(H,80,100)(H,81,101)(H,82,95)(H,83,96)(H,84,105)(H,85,106)(H,86,108)(H,87,99)(H,88,104)(H,89,103)(H,90,102)(H,97,98)(H4,69,70,75)(H4,71,72,76)(H4,73,74,77)/t35-,36-,39-,40-,41-,42-,43-,44-,45-,46-,52-,53-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Patents	Article PubMed	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Ltd Curated by ChEMBL					Assay Description Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubat...				Bioorg Med Chem Lett 27: 3542-3545 (2017) Article DOI: 10.1016/j.bmcl.2017.05.061 BindingDB Entry DOI: 10.7270/Q2F19241
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50450993 (CHEMBL4210786) Show SMILES CC[C@](C)(NC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H](CO)NC(=O)c1c[nH]cn1)C(=O)N[C@@H](Cc1ccncc1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CC(C)(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C85H141N27O20/c1-9-85(8,111-76(128)62-39-50(115)43-112(62)78(130)61(44-113)107-74(126)60-42-95-45-98-60)80(132)108-57(38-49-29-34-94-35-30-49)71(123)104-56(37-48-22-14-11-15-23-48)70(122)106-59(41-83(3,4)5)73(125)105-58(40-64(88)117)72(124)100-53(24-16-17-31-86)75(127)110-84(6,7)79(131)109-65(46(2)114)77(129)102-52(26-19-33-97-82(92)93)67(119)101-54(27-28-63(87)116)69(121)99-51(25-18-32-96-81(90)91)68(120)103-55(66(89)118)36-47-20-12-10-13-21-47/h29-30,34-35,42,45-48,50-59,61-62,65,113-115H,9-28,31-33,36-41,43-44,86H2,1-8H3,(H2,87,116)(H2,88,117)(H2,89,118)(H,95,98)(H,99,121)(H,100,124)(H,101,119)(H,102,129)(H,103,120)(H,104,123)(H,105,125)(H,106,122)(H,107,126)(H,108,132)(H,109,131)(H,110,127)(H,111,128)(H4,90,91,96)(H4,92,93,97)/t46-,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,61+,62-,65+,85+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.310	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair
Melanin-concentrating hormone receptor 1 (Homo sapiens (Human))	BDBM50383116 (CHEMBL2031736) Show SMILES Cc1c(NC(=O)c2ccc(cc2)-c2ccc(Cl)cc2)ccc2cc(CN3CCCC3)cnc12 Show InChI InChI=1S/C28H26ClN3O/c1-19-26(13-10-24-16-20(17-30-27(19)24)18-32-14-2-3-15-32)31-28(33)23-6-4-21(5-7-23)22-8-11-25(29)12-9-22/h4-13,16-17H,2-3,14-15,18H2,1H3,(H,31,33)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.360	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Limited Curated by ChEMBL					Assay Description Displacement of [125I]MCH from human MCHR1 expressed in CHO cells after 1 hr by scintillation counting				J Med Chem 55: 2353-66 (2012) Article DOI: 10.1021/jm201596h BindingDB Entry DOI: 10.7270/Q2GH9JZQ
					More data for this Ligand-Target Pair
Atrial natriuretic peptide receptor 3 (Homo sapiens (Human))	BDBM50254093 (CHEMBL4071568) Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC1CCCCC1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](N)Cc1ccccc1)[C@@H](C)CC)C(=O)NCC(N)=O |r| Show InChI InChI=1S/C58H97N19O15/c1-6-31(3)46(55(91)67-27-42(60)79)76-52(88)38(21-15-23-66-58(63)64)73-54(90)40(26-45(82)83)74-56(92)47(32(4)7-2)77-51(87)37(20-14-22-65-57(61)62)71-43(80)28-68-48(84)33(5)70-53(89)39(25-35-18-12-9-13-19-35)72-44(81)29-69-50(86)41(30-78)75-49(85)36(59)24-34-16-10-8-11-17-34/h8,10-11,16-17,31-33,35-41,46-47,78H,6-7,9,12-15,18-30,59H2,1-5H3,(H2,60,79)(H,67,91)(H,68,84)(H,69,86)(H,70,89)(H,71,80)(H,72,81)(H,73,90)(H,74,92)(H,75,85)(H,76,88)(H,77,87)(H,82,83)(H4,61,62,65)(H4,63,64,66)/t31-,32-,33+,36+,37-,38-,39-,40-,41-,46-,47-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.360	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Ltd Curated by ChEMBL					Assay Description Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubat...				Bioorg Med Chem Lett 27: 3542-3545 (2017) Article DOI: 10.1016/j.bmcl.2017.05.061 BindingDB Entry DOI: 10.7270/Q2F19241
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50450996 (CHEMBL4212927) Show SMILES CC[C@](C)(NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](Cc1ccncc1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CC(C)(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C83H141N25O19/c1-10-83(9,107-74(123)61-29-21-39-108(61)76(125)60(45-109)95-47(3)111)78(127)104-57(42-50-32-37-92-38-33-50)70(119)101-56(41-49-24-15-12-16-25-49)69(118)103-59(44-81(4,5)6)72(121)102-58(43-63(86)113)71(120)97-53(26-17-18-34-84)73(122)106-82(7,8)77(126)105-64(46(2)110)75(124)99-52(28-20-36-94-80(90)91)66(115)98-54(30-31-62(85)112)68(117)96-51(27-19-35-93-79(88)89)67(116)100-55(65(87)114)40-48-22-13-11-14-23-48/h32-33,37-38,46,48-49,51-61,64,109-110H,10-31,34-36,39-45,84H2,1-9H3,(H2,85,112)(H2,86,113)(H2,87,114)(H,95,111)(H,96,117)(H,97,120)(H,98,115)(H,99,124)(H,100,116)(H,101,119)(H,102,121)(H,103,118)(H,104,127)(H,105,126)(H,106,122)(H,107,123)(H4,88,89,93)(H4,90,91,94)/t46-,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61-,64+,83+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50451008 (CHEMBL4211953) Show SMILES C[C@@H](O)[C@H](NC(=O)C(C)(C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)C(C)(C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1ccncc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)C(C)(C)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C80H138N28O19/c1-43(110)60(71(124)99-49(26-18-34-93-76(87)88)62(115)98-52(28-29-58(82)112)65(118)96-48(25-17-33-92-75(85)86)63(116)100-53(61(84)114)38-45-20-11-9-12-21-45)105-74(127)80(7,8)106-68(121)51(24-15-16-32-81)97-67(120)56(41-59(83)113)104-73(126)79(5,6)107-69(122)55(39-46-22-13-10-14-23-46)102-66(119)54(40-47-30-36-91-37-31-47)101-64(117)50(27-19-35-94-77(89)90)103-72(125)78(3,4)108-70(123)57(42-109)95-44(2)111/h30-31,36-37,43,45-46,48-57,60,109-110H,9-29,32-35,38-42,81H2,1-8H3,(H2,82,112)(H2,83,113)(H2,84,114)(H,95,111)(H,96,118)(H,97,120)(H,98,115)(H,99,124)(H,100,116)(H,101,117)(H,102,119)(H,103,125)(H,104,126)(H,105,127)(H,106,121)(H,107,122)(H,108,123)(H4,85,86,92)(H4,87,88,93)(H4,89,90,94)/t43-,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,60+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.410	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50451027 (CHEMBL4211310) Show SMILES CC[C@](C)(NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1ccncc1)NC(=O)[C@](C)(CC)NC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H](CO)NC(=O)c1c[nH]cn1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C83H137N27O20/c1-8-82(6,108-72(124)56(37-47-22-14-11-15-23-47)102-68(120)55(38-48-29-34-92-35-30-48)104-78(130)83(7,9-2)109-73(125)60-39-49(113)42-110(60)75(127)59(43-111)103-70(122)58-41-93-44-96-58)77(129)105-57(40-62(86)115)69(121)98-52(24-16-17-31-84)71(123)107-81(4,5)76(128)106-63(45(3)112)74(126)100-51(26-19-33-95-80(90)91)65(117)99-53(27-28-61(85)114)67(119)97-50(25-18-32-94-79(88)89)66(118)101-54(64(87)116)36-46-20-12-10-13-21-46/h29-30,34-35,41,44-47,49-57,59-60,63,111-113H,8-28,31-33,36-40,42-43,84H2,1-7H3,(H2,85,114)(H2,86,115)(H2,87,116)(H,93,96)(H,97,119)(H,98,121)(H,99,117)(H,100,126)(H,101,118)(H,102,120)(H,103,122)(H,104,130)(H,105,129)(H,106,128)(H,107,123)(H,108,124)(H,109,125)(H4,88,89,94)(H4,90,91,95)/t45-,49+,50+,51+,52+,53+,54+,55+,56+,57+,59+,60-,63+,82+,83+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.440	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50451025 (CHEMBL4204797) Show SMILES CC[C@](C)(NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C80H138N28O19/c1-9-80(8,107-70(122)54(36-46-22-14-11-15-23-46)102-67(119)55(37-47-39-90-41-94-47)103-65(117)49(25-17-31-92-77(86)87)98-71(123)58-27-19-33-108(58)73(125)57(40-109)95-44(5)111)75(127)104-56(38-60(82)113)68(120)101-53(34-42(2)3)69(121)106-79(6,7)74(126)105-61(43(4)110)72(124)99-50(26-18-32-93-78(88)89)63(115)97-51(28-29-59(81)112)66(118)96-48(24-16-30-91-76(84)85)64(116)100-52(62(83)114)35-45-20-12-10-13-21-45/h39,41-43,45-46,48-58,61,109-110H,9-38,40H2,1-8H3,(H2,81,112)(H2,82,113)(H2,83,114)(H,90,94)(H,95,111)(H,96,118)(H,97,115)(H,98,123)(H,99,124)(H,100,116)(H,101,120)(H,102,119)(H,103,117)(H,104,127)(H,105,126)(H,106,121)(H,107,122)(H4,84,85,91)(H4,86,87,92)(H4,88,89,93)/t43-,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,58-,61+,80+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.450	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50451030 (CHEMBL4216864) Show SMILES CC[C@](C)(NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1ccncc1)NC(=O)[C@](C)(CC)NC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C81H137N25O20/c1-9-80(7,104-70(120)56(38-47-23-15-12-16-24-47)99-67(117)55(39-48-30-35-90-36-31-48)100-76(126)81(8,10-2)105-71(121)59-40-49(110)42-106(59)73(123)58(43-107)93-45(4)109)75(125)101-57(41-61(84)112)68(118)95-52(25-17-18-32-82)69(119)103-79(5,6)74(124)102-62(44(3)108)72(122)97-51(27-20-34-92-78(88)89)64(114)96-53(28-29-60(83)111)66(116)94-50(26-19-33-91-77(86)87)65(115)98-54(63(85)113)37-46-21-13-11-14-22-46/h30-31,35-36,44,46-47,49-59,62,107-108,110H,9-29,32-34,37-43,82H2,1-8H3,(H2,83,111)(H2,84,112)(H2,85,113)(H,93,109)(H,94,116)(H,95,118)(H,96,114)(H,97,122)(H,98,115)(H,99,117)(H,100,126)(H,101,125)(H,102,124)(H,103,119)(H,104,120)(H,105,121)(H4,86,87,91)(H4,88,89,92)/t44-,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59-,62+,80+,81+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.460	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50269185 (CHEMBL4069788) Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1ccncc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C86H145N27O19/c1-47(2)40-59(78(128)112-86(5,6)82(132)111-68(48(3)115)80(130)104-56(28-18-36-99-85(94)95)70(120)102-57(30-31-66(87)117)73(123)101-54(26-16-34-97-83(90)91)71(121)105-58(69(89)119)41-50-20-10-7-11-21-50)106-77(127)63(45-67(88)118)110-76(126)61(43-52-24-14-9-15-25-52)109-74(124)60(42-51-22-12-8-13-23-51)108-75(125)62(44-53-32-37-96-38-33-53)107-72(122)55(27-17-35-98-84(92)93)103-79(129)65-29-19-39-113(65)81(131)64(46-114)100-49(4)116/h32-33,37-38,47-48,50-52,54-65,68,114-115H,7-31,34-36,39-46H2,1-6H3,(H2,87,117)(H2,88,118)(H2,89,119)(H,100,116)(H,101,123)(H,102,120)(H,103,129)(H,104,130)(H,105,121)(H,106,127)(H,107,122)(H,108,125)(H,109,124)(H,110,126)(H,111,132)(H,112,128)(H4,90,91,97)(H4,92,93,98)(H4,94,95,99)/t48-,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65-,68+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.490	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]peptide YY from human Y2 receptor expressed in CHO cell membranes after 60 mins by TopCount scintillation counting analysis				Bioorg Med Chem Lett 27: 3829-3832 (2017) Article DOI: 10.1016/j.bmcl.2017.06.055 BindingDB Entry DOI: 10.7270/Q2MK6GC2
					More data for this Ligand-Target Pair
Atrial natriuretic peptide receptor 3 (Homo sapiens (Human))	BDBM50254081 (CHEMBL4103929) Show SMILES CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](C)NC(=O)CNC1=O)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC |r| Show InChI InChI=1S/C64H106N24O20S2/c1-6-31(3)48-59(105)77-26-45(92)78-33(5)50(96)86-43(61(107)108)30-110-109-29-42(85-57(103)41(28-90)84-56(102)40(27-89)83-51(97)35(65)16-11-19-72-62(66)67)58(104)81-38(22-34-14-9-8-10-15-34)52(98)76-24-44(91)75-25-46(93)79-36(17-12-20-73-63(68)69)53(99)88-49(32(4)7-2)60(106)82-39(23-47(94)95)55(101)80-37(54(100)87-48)18-13-21-74-64(70)71/h8-10,14-15,31-33,35-43,48-49,89-90H,6-7,11-13,16-30,65H2,1-5H3,(H,75,91)(H,76,98)(H,77,105)(H,78,92)(H,79,93)(H,80,101)(H,81,104)(H,82,106)(H,83,97)(H,84,102)(H,85,103)(H,86,96)(H,87,100)(H,88,99)(H,94,95)(H,107,108)(H4,66,67,72)(H4,68,69,73)(H4,70,71,74)/t31-,32-,33-,35-,36-,37-,38-,39-,40-,41-,42-,43-,48-,49-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.510	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Ltd Curated by ChEMBL					Assay Description Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubat...				Bioorg Med Chem Lett 27: 3542-3545 (2017) Article DOI: 10.1016/j.bmcl.2017.05.061 BindingDB Entry DOI: 10.7270/Q2F19241
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50450998 (CHEMBL4207590) Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(=O)c1c[nH]cn1)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C86H144N30O19/c1-46(2)35-57(78(131)115-86(4,5)82(135)114-67(47(3)118)80(133)106-54(27-17-33-100-85(94)95)69(122)104-55(29-30-65(87)119)72(125)103-52(25-15-31-98-83(90)91)70(123)107-56(68(89)121)36-48-19-9-6-10-20-48)108-76(129)61(40-66(88)120)112-74(127)59(38-50-23-13-8-14-24-50)109-73(126)58(37-49-21-11-7-12-22-49)110-75(128)60(39-51-41-96-44-101-51)111-71(124)53(26-16-32-99-84(92)93)105-79(132)64-28-18-34-116(64)81(134)63(43-117)113-77(130)62-42-97-45-102-62/h41-42,44-50,52-61,63-64,67,117-118H,6-40,43H2,1-5H3,(H2,87,119)(H2,88,120)(H2,89,121)(H,96,101)(H,97,102)(H,103,125)(H,104,122)(H,105,132)(H,106,133)(H,107,123)(H,108,129)(H,109,126)(H,110,128)(H,111,124)(H,112,127)(H,113,130)(H,114,135)(H,115,131)(H4,90,91,98)(H4,92,93,99)(H4,94,95,100)/t47-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,63+,64-,67+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.510	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair
Atrial natriuretic peptide receptor 3 (Homo sapiens (Human))	BDBM50254088 (CHEMBL4088351) Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(=O)NCC(N)=O |r| Show InChI InChI=1S/C60H100N20O17/c1-5-32(3)48(57(96)70-26-43(62)83)79-54(93)38(20-14-22-68-60(65)66)75-56(95)41(25-47(87)88)77-58(97)49(33(4)6-2)80-53(92)37(19-13-21-67-59(63)64)73-45(85)28-69-44(84)27-71-51(90)39(23-34-15-9-7-10-16-34)74-46(86)29-72-52(91)42(31-82)78-55(94)40(76-50(89)36(61)30-81)24-35-17-11-8-12-18-35/h8,11-12,17-18,32-34,36-42,48-49,81-82H,5-7,9-10,13-16,19-31,61H2,1-4H3,(H2,62,83)(H,69,84)(H,70,96)(H,71,90)(H,72,91)(H,73,85)(H,74,86)(H,75,95)(H,76,89)(H,77,97)(H,78,94)(H,79,93)(H,80,92)(H,87,88)(H4,63,64,67)(H4,65,66,68)/t32-,33-,36-,37-,38-,39-,40-,41-,42-,48-,49-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.520	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Ltd Curated by ChEMBL					Assay Description Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubat...				Bioorg Med Chem Lett 27: 3542-3545 (2017) Article DOI: 10.1016/j.bmcl.2017.05.061 BindingDB Entry DOI: 10.7270/Q2F19241
					More data for this Ligand-Target Pair
5-hydroxytryptamine receptor 2C (Homo sapiens (Human))	BDBM50351324 (CHEMBL1818901) Show SMILES Fc1ccc(cc1)-c1ccc(cc1)C(=O)Nc1ccc2C=C(CN3CCCC3)CCc2c1 |t:22| Show InChI InChI=1S/C28H27FN2O/c29-26-12-9-22(10-13-26)21-5-7-23(8-6-21)28(32)30-27-14-11-24-17-20(3-4-25(24)18-27)19-31-15-1-2-16-31/h5-14,17-18H,1-4,15-16,19H2,(H,30,32)	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	Article PubMed	n/a	n/a	0.530	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Limited Curated by ChEMBL					Assay Description Displacement of [3H]mesulergine from human 5HT2C receptor expressed in CHO cells after 1 hr by scintillation counting				J Med Chem 55: 2353-66 (2012) Article DOI: 10.1021/jm201596h BindingDB Entry DOI: 10.7270/Q2GH9JZQ
					More data for this Ligand-Target Pair
Melanin-concentrating hormone receptor 1 (Homo sapiens (Human))	BDBM50383114 (CHEMBL2031734) Show SMILES COc1ccc(cc1)-c1ccc(cc1)C(=O)Nc1ccc2cc(CN3CCCC3)cnc2c1C Show InChI InChI=1S/C29H29N3O2/c1-20-27(14-11-25-17-21(18-30-28(20)25)19-32-15-3-4-16-32)31-29(33)24-7-5-22(6-8-24)23-9-12-26(34-2)13-10-23/h5-14,17-18H,3-4,15-16,19H2,1-2H3,(H,31,33)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.530	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Limited Curated by ChEMBL					Assay Description Displacement of [125I]MCH from human MCHR1 expressed in CHO cells after 1 hr by scintillation counting				J Med Chem 55: 2353-66 (2012) Article DOI: 10.1021/jm201596h BindingDB Entry DOI: 10.7270/Q2GH9JZQ
					More data for this Ligand-Target Pair
Melanin-concentrating hormone receptor 1 (Homo sapiens (Human))	BDBM50383112 (CHEMBL2029372) Show SMILES Cc1c(NC(=O)c2ccc(cc2)-c2ccc(F)cc2)ccc2cc(CN3CCCC3)cnc12 Show InChI InChI=1S/C28H26FN3O/c1-19-26(13-10-24-16-20(17-30-27(19)24)18-32-14-2-3-15-32)31-28(33)23-6-4-21(5-7-23)22-8-11-25(29)12-9-22/h4-13,16-17H,2-3,14-15,18H2,1H3,(H,31,33)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.540	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Co., Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]MCH from human MCHR1 expressed in CHO cells after 60 mins by liquid scintillation counting				J Med Chem 55: 4336-51 (2012) Article DOI: 10.1021/jm300167z BindingDB Entry DOI: 10.7270/Q2JS9RHR
					More data for this Ligand-Target Pair
Melanin-concentrating hormone receptor 1 (Homo sapiens (Human))	BDBM50383112 (CHEMBL2029372) Show SMILES Cc1c(NC(=O)c2ccc(cc2)-c2ccc(F)cc2)ccc2cc(CN3CCCC3)cnc12 Show InChI InChI=1S/C28H26FN3O/c1-19-26(13-10-24-16-20(17-30-27(19)24)18-32-14-2-3-15-32)31-28(33)23-6-4-21(5-7-23)22-8-11-25(29)12-9-22/h4-13,16-17H,2-3,14-15,18H2,1H3,(H,31,33)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.540	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Limited Curated by ChEMBL					Assay Description Displacement of [125I]MCH from human MCHR1 expressed in CHO cells after 1 hr by scintillation counting				J Med Chem 55: 2353-66 (2012) Article DOI: 10.1021/jm201596h BindingDB Entry DOI: 10.7270/Q2GH9JZQ
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50269166 (CHEMBL4063306) Show SMILES C[C@@H](O)[C@H](NC(=O)C(C)(C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C84H145N29O19/c1-46(115)66(78(130)105-54(29-18-36-98-83(93)94)68(120)103-56(31-32-64(86)117)71(123)101-52(27-16-34-96-81(89)90)69(121)106-57(67(88)119)38-48-20-8-5-9-21-48)111-80(132)84(3,4)112-76(128)55(26-14-15-33-85)102-75(127)61(42-65(87)118)110-73(125)59(40-50-24-12-7-13-25-50)107-72(124)58(39-49-22-10-6-11-23-49)108-74(126)60(41-51-43-95-45-99-51)109-70(122)53(28-17-35-97-82(91)92)104-77(129)63-30-19-37-113(63)79(131)62(44-114)100-47(2)116/h43,45-46,48-50,52-63,66,114-115H,5-42,44,85H2,1-4H3,(H2,86,117)(H2,87,118)(H2,88,119)(H,95,99)(H,100,116)(H,101,123)(H,102,127)(H,103,120)(H,104,129)(H,105,130)(H,106,121)(H,107,124)(H,108,126)(H,109,122)(H,110,125)(H,111,132)(H,112,128)(H4,89,90,96)(H4,91,92,97)(H4,93,94,98)/t46-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63-,66+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.550	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]peptide YY from human Y2 receptor expressed in CHO cell membranes after 60 mins by TopCount scintillation counting analysis				Bioorg Med Chem Lett 27: 3829-3832 (2017) Article DOI: 10.1016/j.bmcl.2017.06.055 BindingDB Entry DOI: 10.7270/Q2MK6GC2
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50197025 (CHEMBL439904 | PYY(3-36)) Show SMILES CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O Show InChI InChI=1S/C180H279N53O54/c1-17-91(12)141(185)171(282)214-114(27-18-19-61-181)175(286)232-67-25-33-130(232)169(280)211-111(53-58-137(247)248)147(258)204-94(15)174(285)231-66-24-32-129(231)168(279)200-82-135(244)205-109(52-57-136(245)246)152(263)226-126(80-140(253)254)157(268)203-93(14)146(257)228-128(84-235)176(287)233-68-26-34-131(233)170(281)212-113(55-60-139(251)252)154(265)210-112(54-59-138(249)250)155(266)216-117(70-87(4)5)159(270)224-124(78-133(183)242)164(275)208-106(29-21-63-197-178(189)190)150(261)220-121(75-98-39-47-103(239)48-40-98)162(273)221-120(74-97-37-45-102(238)46-38-97)156(267)202-92(13)145(256)227-127(83-234)167(278)219-116(69-86(2)3)158(269)207-107(30-22-64-198-179(191)192)151(262)223-123(77-100-81-195-85-201-100)163(274)222-122(76-99-41-49-104(240)50-42-99)161(272)217-118(71-88(6)7)160(271)225-125(79-134(184)243)165(276)218-119(72-89(8)9)166(277)229-142(90(10)11)172(283)230-143(95(16)236)173(284)213-108(31-23-65-199-180(193)194)148(259)209-110(51-56-132(182)241)153(264)206-105(28-20-62-196-177(187)188)149(260)215-115(144(186)255)73-96-35-43-101(237)44-36-96/h35-50,81,85-95,105-131,141-143,234-240H,17-34,51-80,82-84,181,185H2,1-16H3,(H2,182,241)(H2,183,242)(H2,184,243)(H2,186,255)(H,195,201)(H,200,279)(H,202,267)(H,203,268)(H,204,258)(H,205,244)(H,206,264)(H,207,269)(H,208,275)(H,209,259)(H,210,265)(H,211,280)(H,212,281)(H,213,284)(H,214,282)(H,215,260)(H,216,266)(H,217,272)(H,218,276)(H,219,278)(H,220,261)(H,221,273)(H,222,274)(H,223,262)(H,224,270)(H,225,271)(H,226,263)(H,227,256)(H,228,257)(H,229,277)(H,230,283)(H,245,246)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H4,187,188,196)(H4,189,190,197)(H4,191,192,198)(H4,193,194,199)/t91-,92-,93-,94-,95+,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,141-,142-,143-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.570	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50450997 (CHEMBL4202723) Show SMILES CC[C@](C)(NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1ccncc1)NC(=O)[C@](C)(CC)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C81H137N25O19/c1-9-80(7,104-70(119)56(41-48-24-15-12-16-25-48)99-67(116)55(42-49-32-37-90-38-33-49)100-76(125)81(8,10-2)105-71(120)59-29-21-39-106(59)73(122)58(44-107)93-46(4)109)75(124)101-57(43-61(84)111)68(117)95-52(26-17-18-34-82)69(118)103-79(5,6)74(123)102-62(45(3)108)72(121)97-51(28-20-36-92-78(88)89)64(113)96-53(30-31-60(83)110)66(115)94-50(27-19-35-91-77(86)87)65(114)98-54(63(85)112)40-47-22-13-11-14-23-47/h32-33,37-38,45,47-48,50-59,62,107-108H,9-31,34-36,39-44,82H2,1-8H3,(H2,83,110)(H2,84,111)(H2,85,112)(H,93,109)(H,94,115)(H,95,117)(H,96,113)(H,97,121)(H,98,114)(H,99,116)(H,100,125)(H,101,124)(H,102,123)(H,103,118)(H,104,119)(H,105,120)(H4,86,87,91)(H4,88,89,92)/t45-,50+,51+,52+,53+,54+,55+,56+,57+,58+,59-,62+,80+,81+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.570	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50197025 (CHEMBL439904 | PYY(3-36)) Show SMILES CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O Show InChI InChI=1S/C180H279N53O54/c1-17-91(12)141(185)171(282)214-114(27-18-19-61-181)175(286)232-67-25-33-130(232)169(280)211-111(53-58-137(247)248)147(258)204-94(15)174(285)231-66-24-32-129(231)168(279)200-82-135(244)205-109(52-57-136(245)246)152(263)226-126(80-140(253)254)157(268)203-93(14)146(257)228-128(84-235)176(287)233-68-26-34-131(233)170(281)212-113(55-60-139(251)252)154(265)210-112(54-59-138(249)250)155(266)216-117(70-87(4)5)159(270)224-124(78-133(183)242)164(275)208-106(29-21-63-197-178(189)190)150(261)220-121(75-98-39-47-103(239)48-40-98)162(273)221-120(74-97-37-45-102(238)46-38-97)156(267)202-92(13)145(256)227-127(83-234)167(278)219-116(69-86(2)3)158(269)207-107(30-22-64-198-179(191)192)151(262)223-123(77-100-81-195-85-201-100)163(274)222-122(76-99-41-49-104(240)50-42-99)161(272)217-118(71-88(6)7)160(271)225-125(79-134(184)243)165(276)218-119(72-89(8)9)166(277)229-142(90(10)11)172(283)230-143(95(16)236)173(284)213-108(31-23-65-199-180(193)194)148(259)209-110(51-56-132(182)241)153(264)206-105(28-20-62-196-177(187)188)149(260)215-115(144(186)255)73-96-35-43-101(237)44-36-96/h35-50,81,85-95,105-131,141-143,234-240H,17-34,51-80,82-84,181,185H2,1-16H3,(H2,182,241)(H2,183,242)(H2,184,243)(H2,186,255)(H,195,201)(H,200,279)(H,202,267)(H,203,268)(H,204,258)(H,205,244)(H,206,264)(H,207,269)(H,208,275)(H,209,259)(H,210,265)(H,211,280)(H,212,281)(H,213,284)(H,214,282)(H,215,260)(H,216,266)(H,217,272)(H,218,276)(H,219,278)(H,220,261)(H,221,273)(H,222,274)(H,223,262)(H,224,270)(H,225,271)(H,226,263)(H,227,256)(H,228,257)(H,229,277)(H,230,283)(H,245,246)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H4,187,188,196)(H4,189,190,197)(H4,191,192,198)(H4,193,194,199)/t91-,92-,93-,94-,95+,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,141-,142-,143-/m0/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.570	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]peptide YY from human Y2 receptor expressed in CHO cell membranes after 60 mins by TopCount scintillation counting analysis				Bioorg Med Chem Lett 27: 3829-3832 (2017) Article DOI: 10.1016/j.bmcl.2017.06.055 BindingDB Entry DOI: 10.7270/Q2MK6GC2
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50450994 (CHEMBL4206938) Show SMILES CC[C@](C)(NC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](Cc1ccncc1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CC(C)(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C83H141N25O20/c1-10-83(9,107-74(124)61-40-50(112)43-108(61)76(126)60(44-109)95-46(3)111)78(128)104-57(39-49-30-35-92-36-31-49)70(120)101-56(38-48-23-15-12-16-24-48)69(119)103-59(42-81(4,5)6)72(122)102-58(41-63(86)114)71(121)97-53(25-17-18-32-84)73(123)106-82(7,8)77(127)105-64(45(2)110)75(125)99-52(27-20-34-94-80(90)91)66(116)98-54(28-29-62(85)113)68(118)96-51(26-19-33-93-79(88)89)67(117)100-55(65(87)115)37-47-21-13-11-14-22-47/h30-31,35-36,45,47-48,50-61,64,109-110,112H,10-29,32-34,37-44,84H2,1-9H3,(H2,85,113)(H2,86,114)(H2,87,115)(H,95,111)(H,96,118)(H,97,121)(H,98,116)(H,99,125)(H,100,117)(H,101,120)(H,102,122)(H,103,119)(H,104,128)(H,105,127)(H,106,123)(H,107,124)(H4,88,89,93)(H4,90,91,94)/t45-,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61-,64+,83+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.580	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50269168 (CHEMBL4069205) Show SMILES C[C@@H](O)[C@H](NC(=O)C(C)(C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C84H145N31O19/c1-45(117)65(77(132)107-53(27-16-34-99-82(92)93)67(122)105-55(30-31-63(85)119)70(125)103-51(25-14-32-97-80(88)89)68(123)108-56(66(87)121)37-47-19-8-5-9-20-47)113-79(134)84(3,4)114-75(130)54(28-17-35-100-83(94)95)104-74(129)60(41-64(86)120)112-72(127)58(39-49-23-12-7-13-24-49)109-71(126)57(38-48-21-10-6-11-22-48)110-73(128)59(40-50-42-96-44-101-50)111-69(124)52(26-15-33-98-81(90)91)106-76(131)62-29-18-36-115(62)78(133)61(43-116)102-46(2)118/h42,44-45,47-49,51-62,65,116-117H,5-41,43H2,1-4H3,(H2,85,119)(H2,86,120)(H2,87,121)(H,96,101)(H,102,118)(H,103,125)(H,104,129)(H,105,122)(H,106,131)(H,107,132)(H,108,123)(H,109,126)(H,110,128)(H,111,124)(H,112,127)(H,113,134)(H,114,130)(H4,88,89,97)(H4,90,91,98)(H4,92,93,99)(H4,94,95,100)/t45-,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62-,65+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]peptide YY from human Y2 receptor expressed in CHO cell membranes after 60 mins by TopCount scintillation counting analysis				Bioorg Med Chem Lett 27: 3829-3832 (2017) Article DOI: 10.1016/j.bmcl.2017.06.055 BindingDB Entry DOI: 10.7270/Q2MK6GC2
					More data for this Ligand-Target Pair
Atrial natriuretic peptide receptor 3 (Homo sapiens (Human))	BDBM50254097 (CHEMBL4082715) Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(O)=O |r| Show InChI InChI=1S/C64H108N24O20S2/c1-6-31(3)48(59(105)77-26-45(92)78-33(5)50(96)86-43(30-110)61(107)108)87-54(100)37(18-13-21-74-64(70)71)80-55(101)39(23-47(94)95)82-60(106)49(32(4)7-2)88-53(99)36(17-12-20-73-63(68)69)79-46(93)25-75-44(91)24-76-52(98)38(22-34-14-9-8-10-15-34)81-58(104)42(29-109)85-57(103)41(28-90)84-56(102)40(27-89)83-51(97)35(65)16-11-19-72-62(66)67/h8-10,14-15,31-33,35-43,48-49,89-90,109-110H,6-7,11-13,16-30,65H2,1-5H3,(H,75,91)(H,76,98)(H,77,105)(H,78,92)(H,79,93)(H,80,101)(H,81,104)(H,82,106)(H,83,97)(H,84,102)(H,85,103)(H,86,96)(H,87,100)(H,88,99)(H,94,95)(H,107,108)(H4,66,67,72)(H4,68,69,73)(H4,70,71,74)/t31-,32-,33-,35-,36-,37-,38-,39-,40-,41-,42-,43-,48-,49-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.650	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Ltd Curated by ChEMBL					Assay Description Displacement of [125I]-human ANP from His-tagged and Fc fragment containing human NPR-3 extracellular domain expressed in FreeStyle 293 cells incubat...				Bioorg Med Chem Lett 27: 3542-3545 (2017) Article DOI: 10.1016/j.bmcl.2017.05.061 BindingDB Entry DOI: 10.7270/Q2F19241
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50451026 (CHEMBL4208856) Show SMILES CC[C@@](C)(NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C85H146N28O19/c1-7-85(6,81(132)111-67(47(4)115)79(130)104-55(29-19-35-98-84(93)94)69(120)102-56(31-32-65(86)117)72(123)101-53(27-17-33-96-82(89)90)70(121)105-57(68(88)119)38-49-21-11-8-12-22-49)112-77(128)58(37-46(2)3)106-76(127)62(42-66(87)118)110-74(125)60(40-51-25-15-10-16-26-51)107-73(124)59(39-50-23-13-9-14-24-50)108-75(126)61(41-52-43-95-45-99-52)109-71(122)54(28-18-34-97-83(91)92)103-78(129)64-30-20-36-113(64)80(131)63(44-114)100-48(5)116/h43,45-47,49-51,53-64,67,114-115H,7-42,44H2,1-6H3,(H2,86,117)(H2,87,118)(H2,88,119)(H,95,99)(H,100,116)(H,101,123)(H,102,120)(H,103,129)(H,104,130)(H,105,121)(H,106,127)(H,107,124)(H,108,126)(H,109,122)(H,110,125)(H,111,132)(H,112,128)(H4,89,90,96)(H4,91,92,97)(H4,93,94,98)/t47-,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64-,67+,85-/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.670	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50269163 (CHEMBL4094429) Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C84H144N28O20/c1-44(2)33-57(76(128)111-84(5,6)80(132)110-66(45(3)114)78(130)103-54(27-18-32-97-83(92)93)68(120)101-55(28-29-64(85)117)71(123)100-52(25-16-30-95-81(88)89)69(121)104-56(67(87)119)34-47-19-10-7-11-20-47)105-75(127)61(39-65(86)118)109-73(125)59(36-49-23-14-9-15-24-49)106-72(124)58(35-48-21-12-8-13-22-48)107-74(126)60(37-50-40-94-43-98-50)108-70(122)53(26-17-31-96-82(90)91)102-77(129)63-38-51(116)41-112(63)79(131)62(42-113)99-46(4)115/h40,43-45,47-49,51-63,66,113-114,116H,7-39,41-42H2,1-6H3,(H2,85,117)(H2,86,118)(H2,87,119)(H,94,98)(H,99,115)(H,100,123)(H,101,120)(H,102,129)(H,103,130)(H,104,121)(H,105,127)(H,106,124)(H,107,126)(H,108,122)(H,109,125)(H,110,132)(H,111,128)(H4,88,89,95)(H4,90,91,96)(H4,92,93,97)/t45-,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63-,66+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.700	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]peptide YY from human Y2 receptor expressed in CHO cell membranes after 60 mins by TopCount scintillation counting analysis				Bioorg Med Chem Lett 27: 3829-3832 (2017) Article DOI: 10.1016/j.bmcl.2017.06.055 BindingDB Entry DOI: 10.7270/Q2MK6GC2
					More data for this Ligand-Target Pair
Melanin-concentrating hormone receptor 1 (Homo sapiens (Human))	BDBM50383096 (CHEMBL2031716) Show SMILES Clc1ccc(cc1)-c1ccc(cc1)C(=O)Nc1ccc2cc(CN3CCCC3)cnc2c1 Show InChI InChI=1S/C27H24ClN3O/c28-24-10-7-21(8-11-24)20-3-5-22(6-4-20)27(32)30-25-12-9-23-15-19(17-29-26(23)16-25)18-31-13-1-2-14-31/h3-12,15-17H,1-2,13-14,18H2,(H,30,32)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.740	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Limited Curated by ChEMBL					Assay Description Displacement of [125I]MCH from human MCHR1 expressed in CHO cells after 1 hr by scintillation counting				J Med Chem 55: 2353-66 (2012) Article DOI: 10.1021/jm201596h BindingDB Entry DOI: 10.7270/Q2GH9JZQ
					More data for this Ligand-Target Pair
Melanin-concentrating hormone receptor 1 (Homo sapiens (Human))	BDBM50383091 (CHEMBL2031573) Show SMILES Fc1ccc(cc1)-c1ccc(cc1)C(=O)Nc1ccc2cc(CN3CCCC3)ccc2c1 Show InChI InChI=1S/C28H25FN2O/c29-26-12-9-22(10-13-26)21-5-7-23(8-6-21)28(32)30-27-14-11-24-17-20(3-4-25(24)18-27)19-31-15-1-2-16-31/h3-14,17-18H,1-2,15-16,19H2,(H,30,32)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.760	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Limited Curated by ChEMBL					Assay Description Displacement of [125I]MCH from human MCHR1 expressed in CHO cells after 1 hr by scintillation counting				J Med Chem 55: 2353-66 (2012) Article DOI: 10.1021/jm201596h BindingDB Entry DOI: 10.7270/Q2GH9JZQ
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50450995 (CHEMBL4208023) Show SMILES CC[C@](C)(NC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](Cc1ccncc1)C(=O)N[C@@H](CC1CCCCC1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C80H135N25O20/c1-9-80(8,104-70(120)58-39-48(109)41-105(58)72(122)57(42-106)92-44(3)108)75(125)100-54(38-47-29-34-89-35-30-47)66(116)98-55(37-46-22-14-11-15-23-46)69(119)103-78(4,5)73(123)99-56(40-60(83)111)67(117)94-51(24-16-17-31-81)68(118)102-79(6,7)74(124)101-61(43(2)107)71(121)96-50(26-19-33-91-77(87)88)63(113)95-52(27-28-59(82)110)65(115)93-49(25-18-32-90-76(85)86)64(114)97-53(62(84)112)36-45-20-12-10-13-21-45/h29-30,34-35,43,45-46,48-58,61,106-107,109H,9-28,31-33,36-42,81H2,1-8H3,(H2,82,110)(H2,83,111)(H2,84,112)(H,92,108)(H,93,115)(H,94,117)(H,95,113)(H,96,121)(H,97,114)(H,98,116)(H,99,123)(H,100,125)(H,101,124)(H,102,118)(H,103,119)(H,104,120)(H4,85,86,90)(H4,87,88,91)/t43-,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,58-,61+,80+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.780	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50451029 (CHEMBL4206417) Show SMILES CC[C@](C)(NC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H](CO)NC(=O)c1c[nH]cn1)C(=O)N[C@@H](Cc1ccncc1)C(=O)N[C@@H](CC1CCCCC1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C82H135N27O20/c1-8-82(7,108-72(124)59-38-48(112)41-109(59)74(126)58(42-110)102-69(121)57-40-92-43-95-57)77(129)104-54(37-47-28-33-91-34-29-47)67(119)101-55(36-46-21-13-10-14-22-46)71(123)107-80(3,4)75(127)103-56(39-61(85)114)68(120)97-51(23-15-16-30-83)70(122)106-81(5,6)76(128)105-62(44(2)111)73(125)99-50(25-18-32-94-79(89)90)64(116)98-52(26-27-60(84)113)66(118)96-49(24-17-31-93-78(87)88)65(117)100-53(63(86)115)35-45-19-11-9-12-20-45/h28-29,33-34,40,43-46,48-56,58-59,62,110-112H,8-27,30-32,35-39,41-42,83H2,1-7H3,(H2,84,113)(H2,85,114)(H2,86,115)(H,92,95)(H,96,118)(H,97,120)(H,98,116)(H,99,125)(H,100,117)(H,101,119)(H,102,121)(H,103,127)(H,104,129)(H,105,128)(H,106,122)(H,107,123)(H,108,124)(H4,87,88,93)(H4,89,90,94)/t44-,48+,49+,50+,51+,52+,53+,54+,55+,56+,58+,59-,62+,82+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.910	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair
Melanin-concentrating hormone receptor 1 (Homo sapiens (Human))	BDBM50383092 (CHEMBL2031574) Show SMILES Fc1ccc(cc1)-c1ccc(cc1)C(=O)Nc1ccc2C=C(CN3CCCC3)COc2c1 |t:22| Show InChI InChI=1S/C27H25FN2O2/c28-24-10-7-21(8-11-24)20-3-5-22(6-4-20)27(31)29-25-12-9-23-15-19(18-32-26(23)16-25)17-30-13-1-2-14-30/h3-12,15-16H,1-2,13-14,17-18H2,(H,29,31)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem	Article PubMed	n/a	n/a	0.910	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Limited Curated by ChEMBL					Assay Description Displacement of [125I]MCH from human MCHR1 expressed in CHO cells after 1 hr by scintillation counting				J Med Chem 55: 2353-66 (2012) Article DOI: 10.1021/jm201596h BindingDB Entry DOI: 10.7270/Q2GH9JZQ
					More data for this Ligand-Target Pair
Melanin-concentrating hormone receptor 1 (Homo sapiens (Human))	BDBM50383107 (CHEMBL2031727) Show SMILES Fc1ccc(cc1)-c1ccc(cc1)C(=O)Nc1ccc2cc(CN3CCCC3)cnc2c1F Show InChI InChI=1S/C27H23F2N3O/c28-23-10-7-20(8-11-23)19-3-5-21(6-4-19)27(33)31-24-12-9-22-15-18(16-30-26(22)25(24)29)17-32-13-1-2-14-32/h3-12,15-16H,1-2,13-14,17H2,(H,31,33)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.920	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company Limited Curated by ChEMBL					Assay Description Displacement of [125I]MCH from human MCHR1 expressed in CHO cells after 1 hr by scintillation counting				J Med Chem 55: 2353-66 (2012) Article DOI: 10.1021/jm201596h BindingDB Entry DOI: 10.7270/Q2GH9JZQ
					More data for this Ligand-Target Pair
Neuropeptide Y receptor type 2 (Homo sapiens (Human))	BDBM50269184 (CHEMBL4064778) Show SMILES C[C@@H](O)[C@H](NC(=O)C(C)(C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)C(C)(C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1ccncc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C81H138N28O19/c1-44(111)62(73(125)101-51(26-17-35-95-79(90)91)64(116)99-53(28-29-60(83)113)67(119)97-49(24-15-33-93-77(86)87)65(117)102-54(63(85)115)39-46-19-9-7-10-20-46)106-76(128)81(5,6)107-70(122)52(23-13-14-32-82)98-69(121)57(42-61(84)114)105-75(127)80(3,4)108-71(123)56(40-47-21-11-8-12-22-47)104-68(120)55(41-48-30-36-92-37-31-48)103-66(118)50(25-16-34-94-78(88)89)100-72(124)59-27-18-38-109(59)74(126)58(43-110)96-45(2)112/h30-31,36-37,44,46-47,49-59,62,110-111H,7-29,32-35,38-43,82H2,1-6H3,(H2,83,113)(H2,84,114)(H2,85,115)(H,96,112)(H,97,119)(H,98,121)(H,99,116)(H,100,124)(H,101,125)(H,102,117)(H,103,118)(H,104,120)(H,105,127)(H,106,128)(H,107,122)(H,108,123)(H4,86,87,93)(H4,88,89,94)(H4,90,91,95)/t44-,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59-,62+/m1/s1	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	0.920	n/a	n/a	n/a	n/a	n/a	n/a
Takeda Pharmaceutical Company, Ltd. Curated by ChEMBL					Assay Description Displacement of [125I]-PYY from human neuropeptide Y2 receptor expressed in CHO cell membranes incubated for 60 mins by TopCount based method				Bioorg Med Chem 25: 5718-5725 (2017) Article DOI: 10.1016/j.bmc.2017.08.044 BindingDB Entry DOI: 10.7270/Q23X8969
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 697 total )  |  Next  |  Last  >>

Jump to: